New publication shows ATH434 rescues neurons in MSA model
Filed with ASX · · 3 pages · English
Alterity Therapeutics Ltd. on 6ix
Earlier from Alterity Therapeutics
- Response to ASX Query
- New US Patent for Compounds to Treat Neurodegeneration
- First Regulatory Authorization to Proceed with Phase 2 Trial
- ATH Annual General Meeting Presentation
- Chairmans Address 2021 Annual General Meeting
Later from Alterity Therapeutics
- UK Regulatory Authorisation to Proceed with Phase 2 Trial
- Alterity Launches ATH434 Phase 2 Clinical Trial
- Regulatory Approval to Proceed with Phase 2 Trial in Italy
- Alterity receives a $4.1 million R&D Tax Refund
- First Patient dosed in ATH434 Phase 2 Clinical Trial
Follow Alterity Therapeutics into a list and get an email when it puts out news.
Follow Alterity Therapeutics